A 6-year open-label study of the efficacy and safety of olanzapine long-acting injection in patients with schizophrenia: a post hoc analysis based on the European label recommendation

PURPOSE: To assess the long-term efficacy and safety of olanzapine long-acting injection (LAI) in the treatment of schizophrenia, focusing on clinical trial data consistent with the approved indication and dosing recommendations in the European label and which forms the basis for treatment decisions...

Descripción completa

Detalles Bibliográficos
Autores principales: Anand, Ernie, Berggren, Lovisa, Deix, Claudia, Tóth, Ágoston, McDonnell, David P
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove Medical Press 2015
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4455859/
https://www.ncbi.nlm.nih.gov/pubmed/26064053
http://dx.doi.org/10.2147/NDT.S79347

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4455859/
https://www.ncbi.nlm.nih.gov/pubmed/26064053
http://dx.doi.org/10.2147/NDT.S79347

Ejemplares similares